23ANDME Holding Co A (MEHCQ) Stock Price, News & Analysis

Written before these shares stopped trading.

23andMe Holding Co. (trading under the symbol MEHCQ and later referred to in SEC filings as Chrome Holding Co.) is described in company communications as a genetics-led consumer healthcare and biotechnology company. Across its public statements, the company characterizes its mission as helping people access, understand and gain health benefits through greater understanding of the human genome, and as empowering a healthier future through genetics-led consumer healthcare.

Business focus and activities

In multiple news releases, 23andMe is described as a genetics-led consumer healthcare and biotechnology company and as a genetics-led consumer healthcare company. The business included the Personal Genome Service (PGS) and Research Services business lines, and references are also made to a Total Health business line and the Lemonaid Health business. A later SEC filing notes that for a prior fiscal quarter a substantial majority of the company’s total revenue was generated from its personal genome service business, indicating the importance of that activity within the overall business.

According to transaction disclosures, substantially all of the company’s assets and ongoing business operations, including the Personal Genome Service and Research Services business lines and the Lemonaid Health business, were sold under Section 363 of the U.S. Bankruptcy Code to a nonprofit public benefit corporation that was initially referred to as TTAM Research Institute and later as 23andMe Research Institute. Company communications state that as part of this nonprofit organization, 23andMe is continuing to operate and provide customers with personalized DNA testing and research services, with an emphasis on customer choice and transparency regarding data use and research participation.

Corporate restructuring and Chapter 11 proceedings

SEC filings for Chrome Holding Co. (formerly known as 23andMe Holding Co.) report that on March 23, 2025, the company and certain subsidiaries filed voluntary petitions seeking relief under Chapter 11 of Title 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Eastern District of Missouri. Subsequent filings describe the Chapter 11 cases, the filing and amendment of joint Chapter 11 plans, and the court’s confirmation of a modified plan.

Company disclosures highlight that the Chapter 11 process included a court-supervised sale of substantially all of the company’s assets, with an initial definitive agreement involving Regeneron Pharmaceuticals, Inc. and a later definitive agreement and completed transaction with TTAM Research Institute for the Personal Genome Service, Research Services, and Lemonaid Health business lines. The company also communicated that it had secured debtor-in-possession financing to support operations during the sale process and that the sale process was overseen by a special committee of the board and the bankruptcy court.

Trading status and deregistration

In a news release, 23andMe announced its intention to file a Form 25 Notification of Delisting with the SEC to remove its securities from listing and registration on Nasdaq, following a prior suspension of trading of its Class A common stock on that exchange. The company also stated that once the Nasdaq delisting on Form 25 became effective, it intended to file a Form 15 to deregister with the SEC. A later Form 15 filing by Chrome Holding Co. confirms the termination or suspension of the duty to file reports under specified provisions of the Securities Exchange Act of 1934 for its Class A common stock.

Multiple 8-K filings caution that trading in the company’s Class A common stock during the pendency of the Chapter 11 cases is highly speculative and poses substantial risks, noting that trading prices may bear little or no relationship to any recovery by holders of the common stock in the Chapter 11 cases and that there can be no assurance regarding the liquidity of an active trading market or the prices investors may obtain.

Data privacy, customer data and legal matters

In connection with the court-supervised sale process, 23andMe issued detailed disclosures on the treatment of customer data. The company stated that it requires all bidders to guarantee compliance with the company’s privacy policies and applicable law, and to provide detailed descriptions of intended use of any purchased customer data, privacy programs, and security controls. It also described efforts to appoint independent roles such as a Customer Data Representative or Consumer Privacy Ombudsman to review proposed transactions and their impact on consumer privacy.

Public statements emphasize that 23andMe maintains strict data privacy and security protocols, is subject to consumer privacy and genetic privacy laws, and has adopted these standards company-wide. The company describes extending safeguards to customers globally and operating with a level of transparency that it characterizes as exceeding traditional health care industry standards. In connection with the sale to TTAM Research Institute, the acquirer committed to adhere to 23andMe’s existing privacy policies in perpetuity and to adopt additional consumer protections and privacy safeguards, including honoring existing policies on account and data deletion and research opt-out, customer notification prior to closing, data transfer restrictions, the establishment of a consumer privacy advisory board, and procedures for privacy reporting and breach mitigation.

SEC filings for Chrome Holding Co. also describe various classes of claims and settlements related to data breach matters, including U.S. and Canadian data breach class settlement claims, U.S. data breach arbitration settlement group claims, and Pixel class settlement claims, as part of the company’s Chapter 11 plan. The plan outlines how holders of these claims may receive distributions or settlement benefits, subject to court approval of the respective settlement agreements.

Plan of reorganization and equity treatment

The company’s 8-K filings summarizing the confirmed plan explain that, as of a specified date, the company had outstanding shares of Class A and Class B common stock, and that on the effective date of the plan all outstanding shares of common stock (including shares issuable under equity awards) will be canceled and discharged. Under the plan, holders of interests in the holding company are to receive interests in a plan administration trust as described in the plan and related trust agreement, rather than continuing equity in the reorganized entity.

The plan further details the treatment of various classes of claims and interests, including other secured claims, other priority claims, commercial claims, general unsecured claims, Lemonaid-related claims, intercompany claims and interests, and subordinated claims. These descriptions focus on how each class will receive payment in cash, collateral, or interests in plan administration trusts, or be reinstated or canceled, in accordance with the Bankruptcy Code and the confirmed plan.

Company transformation and current context

Based on the combination of news releases and SEC filings, MEHCQ represents the historical public equity of 23andMe Holding Co., later renamed Chrome Holding Co., which entered Chapter 11 proceedings, conducted a court-supervised sale of substantially all of its assets and ongoing business operations, and moved toward delisting and deregistration of its common stock. The underlying consumer genetics and research operations, including the Personal Genome Service and Research Services business lines and the Lemonaid Health business, were sold to a nonprofit public benefit corporation (TTAM Research Institute, later described as 23andMe Research Institute), which, according to public statements, continues to operate and provide personalized DNA testing and research services under commitments to privacy and data protection.

For investors and researchers, the MEHCQ symbol and related filings therefore provide historical information about a genetics-led consumer healthcare and biotechnology company that underwent a Chapter 11 restructuring, sold substantially all of its operating assets to a nonprofit acquirer, and implemented a confirmed Chapter 11 plan that includes cancellation of existing equity and the establishment of plan administration trust interests for various creditor and equity classes.